Emyria Ltd (ASX:EMD) has selected Eurofins – a world leader in pharmaceutical product testing – to lead an extensive compound screening program for its exclusive MDMA-analogue library.
The analysis plan developed with Eurofins will provide the University of Western Australia (UWA) – Emyria’s drug pipeline development partner – and Emyria itself with insights to inform lead compound identification and further development.
This data will also strengthen the company’s intellectual property portfolio for its MDMA-analogue library.
The first batch of MDMA analogues has been shipped for central nervous system (CNS) activity screening, which Eurofins will perform in a series of targeted CNS screens designed to support the identification and development of analogues in Emyria’s pipeline.
Drug development experts
Eurofins Scientific is one of the global independent market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and for supporting clinical studies.
“We are pleased to be working with global leader Eurofins to screen our first batch of novel MDMA-analogues after successfully completing purity and stability testing at UWA,” Emyria’s managing director Dr Michael Winlo said.
“Eurofins are experts in supporting a complete drug development cycle for new chemical entities and they routinely work with the largest and most innovative biopharmaceutical companies in the world.
“The analysis we have prepared will help Emyria select the most promising drug candidates within the MDMA analogue library for further preclinical evaluation and development.”
Emyria is pioneering new ways to collect, standardise and analyse dynamic patient data and clinical evidence through Emyria Data platform’s collection of deep, ethically sourced clinical evidence gathered from patients across independent clinical trials.
Recently, it secured one of the world’s most sophisticated data platforms after joining Palantir’s Foundry Builders Program.
Read: Emyria gains access to world-class data platform under Palantir Foundry Builders Program
The company is also engaged in developing new care models for patients with unmet needs using novel treatments that bring together patients, clinicians, researchers, and medical innovators.
The MDMA analogy library
Emyria secured exclusive rights to a library of more than 100 novel MDMA analogues when it partnered with the UWA to create a “unique” drug discovery pipeline.
The library of compounds has been compiled by a highly regarded research group led by medicinal chemist, Dr Matt Piggott, who has been working with MDMA analogues and exploring their therapeutic potential, for more than 10 years.
Emyria aims to screen and expand the existing library to identify families of patentable compounds with the greatest promise as new psychedelic-assisted therapies and treatments for other neurological disorders.
Alongside screening, Emyria is leading a global patent strategy, already underway, as well as further clinical development and commercialisation of this unexplored research space.
Emyria’s patent and commercialisation strategy was recently reinforced by an independent expert report from the Therapeutic Goods Administration detailing the therapeutic benefits of MDMA and other psychedelic compounds. The report has potential to result in the down-scheduling of MDMA to a controlled instead of restricted substance in Australia.
Read: Emyria buoyed by TGA-commissioned Independent Expert Report on MDMA and psilocybin
The program has the potential to result in the commercialisation of multiple, novel, central nervous system-active compounds to help treat patients with major unmet needs.
Drug pipeline
